Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Editas Medicine (EDIT)

Editas Medicine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EDIT
DateTimeSourceHeadlineSymbolCompany
13/01/202514:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EDITEditas Medicine Inc
13/01/202514:00GlobeNewswire Inc.Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic PrioritiesNASDAQ:EDITEditas Medicine Inc
06/01/202514:00GlobeNewswire Inc.Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:EDITEditas Medicine Inc
17/12/202421:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EDITEditas Medicine Inc
12/12/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EDITEditas Medicine Inc
12/12/202421:00GlobeNewswire Inc.Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two YearsNASDAQ:EDITEditas Medicine Inc
09/12/202417:00GlobeNewswire Inc.Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual MeetingNASDAQ:EDITEditas Medicine Inc
05/12/202421:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EDITEditas Medicine Inc
05/12/202421:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EDITEditas Medicine Inc
06/11/202414:00GlobeNewswire Inc.Editas Medicine to Participate in Upcoming Investor ConferencesNASDAQ:EDITEditas Medicine Inc
04/11/202412:36Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EDITEditas Medicine Inc
04/11/202412:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EDITEditas Medicine Inc
04/11/202412:30GlobeNewswire Inc.Editas Medicine Announces Third Quarter 2024 Results and Business UpdatesNASDAQ:EDITEditas Medicine Inc
22/10/202411:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EDITEditas Medicine Inc
22/10/202411:00GlobeNewswire Inc.Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic UpdateNASDAQ:EDITEditas Medicine Inc
21/10/202420:30GlobeNewswire Inc.Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing TherapeuticsNASDAQ:EDITEditas Medicine Inc
18/10/202420:01GlobeNewswire Inc.Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of ConceptNASDAQ:EDITEditas Medicine Inc
03/10/202422:00GlobeNewswire Inc.Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare TrustNASDAQ:EDITEditas Medicine Inc
29/08/202420:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EDITEditas Medicine Inc
29/08/202420:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EDITEditas Medicine Inc
28/08/202413:00GlobeNewswire Inc.Editas Medicine to Participate in Upcoming Investor ConferencesNASDAQ:EDITEditas Medicine Inc
07/08/202411:00GlobeNewswire Inc.Editas Medicine Announces Second Quarter 2024 Results and Business UpdatesNASDAQ:EDITEditas Medicine Inc
31/07/202411:00GlobeNewswire Inc.Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate UpdateNASDAQ:EDITEditas Medicine Inc
26/07/202421:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EDITEditas Medicine Inc
14/06/202410:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EDITEditas Medicine Inc
14/06/202407:01GlobeNewswire Inc.Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual CongressNASDAQ:EDITEditas Medicine Inc
14/06/202407:00GlobeNewswire Inc.Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual CongressNASDAQ:EDITEditas Medicine Inc
06/06/202420:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EDITEditas Medicine Inc
06/06/202420:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EDITEditas Medicine Inc
03/06/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EDITEditas Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:EDIT